©2024 Stanford Medicine
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
Recruiting
I'm InterestedTrial ID: NCT05573555
Purpose
The purpose of this clinical trial is to learn about the safety and effects of the study
medicine (called ARV-471) when given together with other medicines for the potential
treatment of advanced or metastatic breast cancer.
This study is seeking participants who have breast cancer that:
- is advanced, may have spread to other organs (metastatic) and cannot be fully treated by
surgery or radiation therapy
- is sensitive to hormonal therapy (it is called estrogen receptor positive); and
- is no longer responding to previous treatments
This study is divided into separate sub-studies.
For Sub-Study B:
All participants will receive ARV-471 and a medicine called ribociclib. ARV-471 and
ribociclib will be given at the same time by mouth, at home, 1 time a day.
The experiences of people receiving the study medicine will be examined. This will help
determine if the study medicine is safe and effective.
Participants will continue to take ARV-471 and ribociclib until their cancer is no longer
responding, or side effects become too severe. They will have visits at the study clinic
about every 4 weeks.
Official Title
TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 YEARS AND OVER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY B (ARV-471 IN COMBINATION WITH RIBOCICLIB)
Stanford Investigator(s)
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Eligibility
Inclusion Criteria:
- histological or cytological diagnosis of ER+ and HER2- advanced/metastatic breast
cancer that is not amendable to surgical resection with curative intent (≥1% ER+
stained cells on the most recent tumor biopsy).
- prior anticancer therapies: at least 1 and no more than 2 lines of prior therapies for
advanced/metastatic disease; 1, and only 1, line of any CDK4/6 inhibitor-based regimen
is required (in any setting eg adjuvant, metastatic)
- at least 1 measurable lesion as defined by RECIST v1.1.
- ECOG PS ≤1.
Exclusion Criteria:
- visceral crisis at risk of life-threatening complications in the short term
- known history of drug-induced pneumonitis or other significant symptomatic
deterioration of lung functions.
- newly diagnosed brain metastases, or symptomatic CNS metastases, carcinomatous
meningitis, or leptomeningeal disease. Participants with a history of CNS metastases
or cord compression are eligible if they have been definitively treated, clinically
stable and discontinued anti-seizure medications and corticosteroids for at least 14
days prior to enrollment in the of study.
- history of any other tumor malignancies within the past 3 years, except for the
following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2)
curatively treated in situ carcinoma of the cervix.
- inflammatory breast cancer
- impaired cardiovascular function or clinically significant cardiovascular diseases
- concurrent administration of medications, food, or herb supplements that are strong
inhibitors and strong/moderate inducers of CYP3A and drugs known to predispose to
Torsade de Pointes or QT interval prolongation.
- renal impairment, not adequate liver function and/or bone marrow function
- known active infection
Intervention(s):
drug: ARV-471
drug: Ribociclib
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Annabel (Grace) Castaneda
650-498-7977